Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Liabilities and Shareholders Equity (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 15 years of Liabilities and Shareholders Equity data on record, last reported at $239.3 million in Q2 2025.

  • For Q2 2025, Liabilities and Shareholders Equity fell 5.76% year-over-year to $239.3 million; the TTM value through May 2025 reached $979.2 million, down 1.25%, while the annual FY2025 figure was $239.3 million, 5.76% down from the prior year.
  • Liabilities and Shareholders Equity reached $239.3 million in Q2 2025 per LFCR's latest filing, up from $237.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $506.9 million in Q1 2021 and bottomed at $236.7 million in Q1 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $304.6 million, with a median of $254.7 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 71.0% in 2021, then tumbled 44.65% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $421.3 million in 2021, then tumbled by 34.5% to $276.0 million in 2022, then decreased by 10.93% to $245.8 million in 2023, then increased by 3.89% to $255.4 million in 2024, then dropped by 6.28% to $239.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $239.3 million in Q2 2025, $237.7 million in Q1 2025, and $255.4 million in Q4 2024.